Abcam, ab115772, Anti-Apolipoprotein A V/APOA5 antibody [2G1H11, 1F1E8]

Size: 100µL
Mouse Monoclonal Apolipoprotein A V/APOA5 antibody. Suitable for WB, sELISA and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human APOA5.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:2G1H11, 1F1E8,
Isotype:IgG1,
Carrier free:No,
Reacts with:Human,
Applications:WB, sELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Fragment Protein within Human APOA5. The exact immunogen used to generate this antibody is proprietary information.Q6Q788

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein G, Purification notes-Purified from tissue culture supernatant., Storage buffer-Preservative: 0.05% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A V also known as APOA5 plays a critical role in lipid metabolism. This protein possesses a molecular weight of approximately 39 kDa and is mainly expressed in the liver. APOA5 modulates the plasma triglyceride levels by enhancing the uptake and clearance of triglyceride-rich lipoproteins. The protein is located at the surface of these lipoproteins facilitating their interaction with receptors and enzymes like lipoprotein lipase.
Biological function summary
APOA5 influences triglyceride metabolism and is part of the HDL particle complex. It interacts directly with lipoprotein lipase to promote the hydrolysis of triglycerides into free fatty acids. This hydrolytic action aids in reducing triglyceride levels in the plasma. APOA5 also indirectly influences very-low-density lipoprotein (VLDL) metabolism reinforcing its role in lipid regulation.
Pathways
APOA5 integrates into the lipoprotein metabolic pathway and the PPAR signaling pathway. In the lipoprotein metabolic pathway APOA5 works with proteins like APOC3 to influence triglyceride homeostasis. This protein is modulated by PPAR-alpha helping control lipid metabolism and energy homeostasis. Its role in these pathways highlights its impact on triglyceride-rich lipoprotein metabolism positioning it as an important player in maintaining lipid balance.
APOA5 strongly associates with hypertriglyceridemia and cardiovascular disease. Variations in the APOA5 gene can lead to abnormal plasma triglyceride levels contributing to the development of hypertriglyceridemia. Additionally APOA5's connection with APOE proteins through lipid metabolism pathways can influence susceptibility to cardiovascular disorders. Understanding the interactions and mutations within APOA5 provides insights into the mechanisms contributing to these disease states.